Eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic Acid (20:5, n-3) (EPA), an ω-3 fatty acid, has been reported to act as a precursor to thromboxanes and prostaglandins (PG). EPA inhibits amino acid oxygenation by PG endoperoxide H synthase-1 and 5-LO (5-lipoxygenase). Experiments have demonstrated the ability of EPA to increase Cafestol palmitate (sc-205613) incorporation into the lipid fraction and decrease the rate of fatty acid oxidation in murine adipose tissue. Additionally, this agent has demonstrated the ability to cause a decrease in gene expression for IL-6 and TNF-α both in skeletal muscle and adipose tissue.
1. Yerram, N.R., et al. 1989. J. Lipid Res. 30: 1747-1757. PMID: 2559136
2. Roth, H.P. and Kirchgessner, M. 1992. Ann. Nutr. Metab. 36: 113-120. PMID: 1354951
3. Wada, M., et al. 2007. J. Biol. Chem. 282: 22254-22266. PMID: 17519235
4. Figueras, M., et al. 2010. Obesity. [Epub ahead of print]. PMID: 20885391
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.